Total Quality
Score
If You Had Traded on This Analysis…
Correct
HIMS
Long Entry
15.8400
2026-02-18
22:41 UTC
Target
16.0700
In 16 Hours
Fail
15.0000
Risk/Reward
1 : 0
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Final PnL
1.45%
P/L: —
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
HIMS stock has experienced a significant decline of over 46% in the last month, following a patent infringement lawsuit filed by Novo Nordisk (NVO) targeting HIMS' semaglutide offerings. This legal action is compounded by an FDA crackdown on unapproved GLP-1 compounding, forcing HIMS to abandon its $49 oral Wegovy alternative. Novo Nordisk, which recently received approval for its weight loss pill and sells it for $149 monthly, is taking legal action against HIMS, alleging patent infringement for selling compounded versions of their treatments at a lower price. This has led to a decline in Novo Nordisk's market share, with an estimated 1 million people using HIMS' compounded knockoff versions. Novo Nordisk is not happy about these developments, as HIMS' actions are undercutting their sales and impacting their market share after billions spent on R&D and regulatory approval.
